JP2013510158A - α‐１プロテイナーゼインヒビターのための組成物、方法およびキット - Google Patents

α‐１プロテイナーゼインヒビターのための組成物、方法およびキット Download PDF

Info

Publication number
JP2013510158A
JP2013510158A JP2012537945A JP2012537945A JP2013510158A JP 2013510158 A JP2013510158 A JP 2013510158A JP 2012537945 A JP2012537945 A JP 2012537945A JP 2012537945 A JP2012537945 A JP 2012537945A JP 2013510158 A JP2013510158 A JP 2013510158A
Authority
JP
Japan
Prior art keywords
api
composition
amino acid
alanine
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012537945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510158A5 (enExample
Inventor
グオ ジャンシン
クロス アンソニー
コールドレン ブレット
バーネット デボラ
マニング マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Therapeutics LLC
Original Assignee
Grifols Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43970713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013510158(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Therapeutics LLC filed Critical Grifols Therapeutics LLC
Publication of JP2013510158A publication Critical patent/JP2013510158A/ja
Publication of JP2013510158A5 publication Critical patent/JP2013510158A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012537945A 2009-11-03 2010-11-02 α‐１プロテイナーゼインヒビターのための組成物、方法およびキット Withdrawn JP2013510158A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25771109P 2009-11-03 2009-11-03
US61/257,711 2009-11-03
PCT/US2010/055135 WO2011056793A2 (en) 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015175001A Division JP6030201B2 (ja) 2009-11-03 2015-09-04 α‐１プロテイナーゼインヒビターのための組成物、方法およびキット

Publications (2)

Publication Number Publication Date
JP2013510158A true JP2013510158A (ja) 2013-03-21
JP2013510158A5 JP2013510158A5 (enExample) 2013-09-26

Family

ID=43970713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537945A Withdrawn JP2013510158A (ja) 2009-11-03 2010-11-02 α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
JP2015175001A Active JP6030201B2 (ja) 2009-11-03 2015-09-04 α‐１プロテイナーゼインヒビターのための組成物、方法およびキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015175001A Active JP6030201B2 (ja) 2009-11-03 2015-09-04 α‐１プロテイナーゼインヒビターのための組成物、方法およびキット

Country Status (19)

Country Link
US (2) US20130131192A1 (enExample)
EP (1) EP2496246B1 (enExample)
JP (2) JP2013510158A (enExample)
KR (1) KR20120114235A (enExample)
CN (1) CN102655876B (enExample)
AU (1) AU2010315325B2 (enExample)
BR (1) BR112012010392B8 (enExample)
CA (1) CA2779369C (enExample)
CL (1) CL2012001159A1 (enExample)
ES (1) ES2679819T3 (enExample)
HU (1) HUE039240T2 (enExample)
IL (1) IL219485A (enExample)
MX (1) MX2012005132A (enExample)
NZ (1) NZ599783A (enExample)
PL (1) PL2496246T3 (enExample)
PT (1) PT2496246T (enExample)
RU (1) RU2555332C2 (enExample)
TR (1) TR201809898T4 (enExample)
WO (1) WO2011056793A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504051A (ja) * 2011-12-30 2015-02-05 グライフォルス・ス・アー 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤
US20210085764A1 (en) * 2016-12-22 2021-03-25 Kamada Ltd. Dry powder formulations of alpha-1 antitrypsin
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
WO2020180390A1 (en) * 2019-03-04 2020-09-10 TAE Life Sciences Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
TW202139973A (zh) 2020-02-25 2021-11-01 愛爾蘭商格里佛全球營運有限公司 獲得α-1蛋白酶抑制劑的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118819A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable antitrypsin
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
JP2002275090A (ja) * 2000-05-08 2002-09-25 Aventis Behring Gmbh 安定化蛋白質調製物およびその調製方法
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5029005B2 (enExample) * 1972-05-08 1975-09-19
JPS597693B2 (ja) 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
DE3581328D1 (de) 1984-06-19 1991-02-21 Transgene Sa Derivate des menschlichen alpha-1-antitrypins und verfahren zu deren herstellung.
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3901917A1 (de) 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
GB8913183D0 (en) 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5032405A (en) 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
JP3479539B2 (ja) 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンｉｉｉ変異体
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
CA2328397A1 (en) 1998-05-12 1999-11-18 Temple University - Of The Commonwealth System Of Higher Education Human antithrombin iiis and methods related thereto
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
US7704958B1 (en) * 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US20030170813A1 (en) 2000-07-05 2003-09-11 Kenichi Suga Process for producing glycoprotein
AU2002335046A1 (en) * 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
EP1558273B1 (en) * 2002-04-25 2011-08-17 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US7777006B2 (en) * 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
DE602004013021T3 (de) 2003-09-22 2012-04-05 Kamada Ltd. Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
WO2005049801A2 (en) 2003-11-14 2005-06-02 Arriva Pharmaceuticals, Inc. Dry protein formulation
US20050226893A1 (en) 2004-03-04 2005-10-13 Jennifer Juneau Lyophilization method to improve excipient crystallization
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
WO2007062040A1 (en) 2005-11-22 2007-05-31 Wyeth Immunoglobulin fusion protein formulations
PT1981572E (pt) 2006-02-09 2013-02-26 Pari Pharma Gmbh Distribuição pulmonar de inibidor de alfa-i proteinase
PL2503995T3 (pl) 2009-11-24 2018-01-31 Grifols Therapeutics Inc Sposoby liofilizacji, kompozycje i zestawy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118819A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable antitrypsin
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
JP2002275090A (ja) * 2000-05-08 2002-09-25 Aventis Behring Gmbh 安定化蛋白質調製物およびその調製方法
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014036439; Ｙａｋｕｇａｋｕ　Ｚａｓｓｈｉ Ｖｏｌ．１２３, 2003, ｐ．９５７-９６１ *

Also Published As

Publication number Publication date
CL2012001159A1 (es) 2012-09-14
IL219485A (en) 2017-06-29
EP2496246B1 (en) 2018-06-27
EP2496246A2 (en) 2012-09-12
BR112012010392A2 (pt) 2016-07-12
KR20120114235A (ko) 2012-10-16
JP6030201B2 (ja) 2016-11-24
PT2496246T (pt) 2018-07-31
ES2679819T8 (es) 2019-01-22
PL2496246T3 (pl) 2018-09-28
CA2779369C (en) 2018-06-19
HUE039240T2 (hu) 2018-12-28
ES2679819T3 (es) 2018-08-31
JP2015221835A (ja) 2015-12-10
US20160106843A1 (en) 2016-04-21
AU2010315325A1 (en) 2012-06-07
CN102655876A (zh) 2012-09-05
WO2011056793A2 (en) 2011-05-12
IL219485A0 (en) 2012-06-28
CN102655876B (zh) 2015-07-15
RU2555332C2 (ru) 2015-07-10
RU2012122793A (ru) 2013-12-10
TR201809898T4 (tr) 2018-07-23
EP2496246A4 (en) 2013-03-27
AU2010315325B2 (en) 2014-11-27
US20130131192A1 (en) 2013-05-23
BR112012010392B1 (pt) 2021-01-05
CA2779369A1 (en) 2011-05-12
WO2011056793A3 (en) 2011-09-29
BR112012010392B8 (pt) 2021-05-25
MX2012005132A (es) 2012-07-25
US9616126B2 (en) 2017-04-11
NZ599783A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
JP6030201B2 (ja) α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
EP1180368B1 (en) Freeze dried hgf preparations
WO1997002832A1 (fr) Preparations lyophilisees de hgf
US12144849B2 (en) Composition comprising highly-concentrated Alpha1 proteinase inhibitor and method for obtaining thereof
JP2006008650A (ja) 凍結乾燥されたアルブミン非含有の再組合わせ人血液凝固第８因子製剤
JP2007511539A (ja) α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
AU2020311050B2 (en) Stable formulations of recombinant proteins
AU2004288854B2 (en) Dry recombinant human alpha 1-antitrypsin formulation
CN102065844A (zh) 干燥转谷氨酰胺酶组合物
RU2813136C1 (ru) Композиция, содержащая высококонцентрированный ингибитор альфа-1-протеиназы, и способ ее приготовления
CN106061495B (zh) 肺内炎症的减弱
NZ755249A (en) Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof
HK40026929A (en) Composition comprising highly-concentrated alpha-1 proteinase inhibitor and method for obtaining thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150908

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151002

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20151015